Thyroid Dysfunction Arising During KEYNOTE-001 Associated with Improved Efficacy of Pembrolizumab in NSCLC Patients at UCLA

被引：1
|
作者：
Lisberg, A. [1 ]
Bornazyan, K. [1 ]
Madrigal, J. [1 ]
Bui, J. [1 ]
Carroll, J. [1 ]
Adame, C. [1 ]
Hunt, J. [1 ]
Lu, H. [1 ]
Noor, Z. [1 ]
Cummings, A. [1 ]
Goldman, J. W. [1 ]
Garon, E. [1 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
NSCLC; anti-PD-1; therapy; Thyroid;
D O I：
10.1016/j.jtho.2017.11.097
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.07-038
引用
收藏
页码：S2430 / S2430
页数：1
相关论文
共 42 条
  • [31] Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and-010.
    Hellmann, Matthew David
    Ma, Junshui
    Garon, Edward B.
    Hui, Rina
    Gandhi, Leena
    Soria, Jean-Charles
    Anderson, Keaven M.
    Lubiniecki, Gregory M.
    Piperdi, Bilal
    Herbst, Roy S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [32] Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.
    Daud, Adil
    Ribas, Antoni
    Robert, Caroline
    Hodi, F. Stephen
    Wolchok, Jedd D.
    Joshua, Anthony M.
    Hwu, Wen-Jen
    Weber, Jeffrey S.
    Gangadhar, Tara C.
    Joseph, Richard Wayne
    Dronca, Roxana Stefania
    Patnaik, Amita
    Zarour, Hassane M.
    Kefford, Richard
    Lindia, Jill Ann
    Li, Xiaoyun Nicole
    Ebbinghaus, Scot
    Kang, Soonmo Peter
    Hamid, Omid
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1-positive advanced NSCLC: Pooled analysis from KEYNOTE-010,-024, and-042
    Nosaki, K.
    Hosomi, Y.
    Saka, H.
    Baas, P.
    de Castro, G., Jr.
    Reck, M.
    Wu, Y-L.
    Brahmer, J. R.
    Felip, E.
    Sawada, T.
    Noguchi, K.
    Han, S. R.
    Piperdi, B.
    Kush, D. A.
    Lopes, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 39 - 39
  • [34] Tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+NSCLC patients
    Griesinger, F.
    Kowanetz, M.
    Zou, W.
    Shames, D. S.
    Cummings, C. A.
    Rizvi, N. A.
    Spira, A.
    Frampton, G.
    Leveque, V.
    Flynn, S.
    Mocci, S.
    Shankar, G.
    Funke, R.
    Ballinger, M.
    Waterkamp, D.
    Chen, D. S.
    Sandler, A.
    Hampton, G.
    Amler, L. C.
    Hedge, P.
    Hellmann, M. D.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 220 - +
  • [35] Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+NSCLC Patients
    Kowanetz, Marcin
    Zou, Wei
    Shames, David
    Cummings, Craig
    Rizvi, Naiyer
    Spira, Alexander
    Frampton, Garrett
    Leveque, Vincent
    Flynn, Susan
    Mocci, Simonetta
    Shankar, Geetha
    Funke, Roel
    Ballinger, Marcus
    Waterkamp, Daniel
    Chen, Daniel
    Sandler, Alan
    Hampton, Garret
    Amler, Lukas
    Hegde, Priti
    Hellmann, Matthew
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S321 - S322
  • [36] Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC
    Kowanetz, M.
    Zou, W.
    Shames, D. S.
    Cummings, C.
    Rizvi, N.
    Spira, A. I.
    Frampton, G. M.
    Leveque, V.
    Flynn, S.
    Mocci, S.
    Shankar, G.
    Funke, R.
    Ballinger, M.
    Waterkamp, D.
    Sandler, A.
    Hampton, G.
    Amler, L.
    Hegde, P. S.
    Hellmann, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients
    Horesh, Adi
    Pollack, Rena
    Nechushtan, Hovav
    Dresner-Pollak, Rivka
    Neuman, Tzahi
    PATHOLOGY & ONCOLOGY RESEARCH, 2023, 29
  • [38] INCREASED BASAL RESTING TONE DURING EMG BIOFEEDBACK IS ASSOCIATED WITH IMPROVED VOIDING FOR PATIENTS WITH ORTHOTOPIC NEOBLADDER DYSFUNCTION
    Stansell, Laura
    Newman, Diane
    Magerfleisch, Laurie
    Wein, Alan
    Guzzo, Thomas
    Malkowicz, S. Bruce
    JOURNAL OF UROLOGY, 2010, 183 (04): : E293 - E293
  • [39] Tumour PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced non small cell lung cancer (NSCLC) Patients
    Neuman, T.
    Vainer, G.
    Horesh, A.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S148 - S148
  • [40] Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179
    Anouti, Bilal
    Althouse, Sandra
    Durm, Greg
    Hanna, Nasser
    CLINICAL LUNG CANCER, 2020, 21 (03) : 288 - 293
12345